Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Fluid Treatments in Sepsis: Recent Trials andRecent Trials and
Meta-AnalysesLauralyn McIntyre MD, FRCP(C), MSc
Scientist, Ottawa Hospital Research InstituteAssistant Professor, University of Ottawa
Department of Epidemiology and Community Medicinep p gy yCentre for Transfusion Research
Chinese Society of Critical Care Medicine Conference Beijing September 14 – 16 2012Beijing, September 14 16, 2012
Conflicts of InterestConflicts of Interest
• CSL Behring g• Baxter Inc• Plasma Protein Therapeutics Association
Why may we use colloid clinically?
PlasmaPlasma
ISS10 L
IC30 L
as a3 L3 L
ISS10 L
IC30 L
For Replacement 10 L 30 L
Blood CellsBlood Cells
10 L 30 L
2 L2 L
Iso-oncotic colloid Hyper-oncotic colloid
Cochrane Systematic Reviews of Fluid Resuscitation
Author/yr Fluids compared # StudiesPerel, 2011 Colloids vs Crystalloids 56
Few Critical Care TrialsOutdated protocols
Bunn, 2011 Colloid vs Colloid 72Alderson 2009 Albumin vs no albumin 37
Heterogenous fluidsDifferent fluid comparators
Different dosesNEJM, 2007
Cochrane 2010 HES vs other fluid 34Different dosesTiming of fluidsHigh risk of bias
So why are we still talking about and studying this question???????
Safe Study Investigators, 2010
International Cross Sectional Study of Resuscitation Fluid Episodes in 391 ICUsResuscitation Fluid Episodes in 391 ICUs
Finfer, S et al Critical Care 2010; 14: 1-24
International Cross Sectional Study of Resuscitation Fluid Episodes in 391 ICUsResuscitation Fluid Episodes in 391 ICUs
Finfer, S et al Critical Care 2010; 14: 1-24
The “type of fluid” question: heightened controversy and new evidencecontroversy and new evidence
Perner et al, NEJM 2012; 367: 124-134
Snap Shot: Use of Colloids Internationally Over Time
AlbuminSynthetic ColloidsSynthetic Colloids
71 6
11.7
71.6
Jones, D et al, Anesthesia and Intensive Care 2010: 38; 266 - 273
What are hydroxyethyl starch (HES) fluids?
• Amylopectin starch (branched chain glucose molecules)• Corn• Corn• Potato
• Rapid hydrolysis via amylase (t1/2 = 10 minutes)• Hydroxyethylation at C2 and C6 carbon units (substitution)
What is the current evidence for hydroxyethyl starch fluids for severehydroxyethyl starch fluids for severe
sepsis and septic shock?
HES and requirement for renal replacement therapy in the critically ill: A meta - analysis
FavoursOdds ratioNo. of events
No. of participantsSt di FavoursOdds ratio
No. of events
No. of participantsSt di
y y y
FavoursHydroxyethyl Starch Favours Control
Odds ratio(95% CI)HES Control
events participantsStudy
Brunkhorst, 2008 26 1.95 (1.30-2.91)81/261 51/272All studies
Studiesn
FavoursHydroxyethyl Starch Favours Control
Odds ratio(95% CI)HES Control
events participantsStudy
Brunkhorst, 2008 26 1.95 (1.30-2.91)81/261 51/272All studies
Studiesn
McIntyre, 2008 28 3.00 (0.28-31.63)Schortgen, 200116 1.20 (0.49-2.93)Cittanova, 1996 27 9.50 (1.09-82.72)
1.90 (1.22- 2.96)
3/21 1/1913/65 11/649/27 1/20
Overall 106/374 64/3754
McIntyre, 2008 28 3.00 (0.28-31.63)Schortgen, 200116 1.20 (0.49-2.93)Cittanova, 1996 27 9.50 (1.09-82.72)
1.90 (1.22- 2.96)
3/21 1/1913/65 11/649/27 1/20
Overall 106/374 64/3754
Patient populationSubgroup analyses
Severe sepsis/septic shock 1.82 (1.27-2.62)Organ transplantation 9 50 (1.09-82.72)
97/347 53/3559/27 1/20
31
Patient populationSubgroup analyses
Severe sepsis/septic shock 1.82 (1.27-2.62)Organ transplantation 9 50 (1.09-82.72)
97/347 53/3559/27 1/20
31
Type of comparator
Organ transplantation 9.50 (1.09 82.72)9/27 1/20
Gelatin 2.64 (0.37-18.96)Crystalloid 1.98 (1.33-2.94)
22/92 12/8484/282 52/291
1
22
Type of comparator
Organ transplantation 9.50 (1.09 82.72)9/27 1/20
Gelatin 2.64 (0.37-18.96)Crystalloid 1.98 (1.33-2.94)
22/92 12/8484/282 52/291
1
22
Odds ratio and 95% CI
0.01 0.1 1 10 100
Odds ratio and 95% CI
0.01 0.1 1 10 100
Zarychanski et al, Open Medicine, 2009: 3; 196 - 209
Perner et al, NEJM 2012; 367: 124-134
• Multi-center randomized double blind controlled trial 798 patients in ICU with severe sepsis who met eligibility criteria within the prior 24 hours
• Tetraspan (6% HES 130/0.42) versus Ringers Acetate• Maximum daily dose 33 mls/kg• Primary Outcome: Mortality or dependence on dialysis at 90 days
Baseline Characteristics HES (n = 398)
Ringers Acetate (n = 400)
Age Median (IQR) 66 (56 – 75) 67 (56 – 76)Age Median (IQR) 66 (56 75) 67 (56 76)Male No (%) 239 (60) 244 (61)SAPS II Median (IQR) 50 (40 – 60) 51 (39 – 62)Shock No (%) 366 (84) 337 (84)Shock No (%) 366 (84) 337 (84)Acute Kidney Injury No (%) 142 (36) 140 (35)Mechanical Ventilation No (%) 240 (60) 245 (61)
Perner et al, NEJM 2012; 367: 124-134
HES Ringers AcetateHES (n = 398)
Ringers Acetate (n = 400)
Fluid 24 hours prior to randomization Median (IQR)
3500 (2000 – 4938) 3000 (2000 – 4868)
HES (n = 398)
Ringers Acetate (n = 400)
Relative Risk95% Confidence
Intervals( Q )
Study Fluid Median (IQR) 3000 (1507 – 5100) 3000 (2000 – 5750)
Open label synthetic colloid No(%) 39 (10) 38 (9.5)
Dead or dialysis dependent 90 days No(%)
202 (51) 173 (43) 1.17 (1.07 – 1.36)
Dead 90 days No(%) 201 (51) 172 (43) 1.17 (1.01 – 1.36)
Doses > protocol maximum No(%) 28 (7)* 41 (10)Dependent on dialysis 90 days No(%)
1 (0.25) 1 (0.25) ---
Renal replacement 87 (22) 65 (16) 1 35 (1 01 – 1 80)
* 2 patients in the HES group received doses higher than maximum recommended from manufacturer (> 50 mls/kg/day
Renal replacement therapy No(%)
87 (22) 65 (16) 1.35 (1.01 1.80)
Insert our updated forrest plot of all HES RCTs t d t CHEST T i l lt tto date, CHEST Trial results to come
Human plasma protein
ALBUMINHuman plasma protein• Derived from pooled plasma• Molecular weight of 66 Kd
S th i d i th li• Synthesized in the liver• Negatively charged• Most common plasma protein (60%)
C t ti i l 40 /L• Concentration in plasma 40 g/L
Available:I i (4 %)– Iso – oncotic (4 – 5%)
– Hyper – oncotic (20 – 25%)
• Responsible for 75 80% oncotic pressure• Responsible for 75-80% oncotic pressure
• Oncotic effect of albumin due to:
Direct effect of albumin: 60%
Gibbs-Donnan effect: 40%
Quinlan, GJ et al, Hepatology, 2005: 41; 1211 - 1219
What are albumin’s functions?
• Maintenance of colloidMaintenance of colloid oncotic pressure
• Transport protein
• Binds inflammatory mediatorsed ato s
• Anti-oxidant effectsAnti oxidant effects
Vincent, JL Best Practise and Research Clinical Anesthesiology 2009; 23: 183 - 191
What is the evidence for albumin as aWhat is the evidence for albumin as a volume resuscitation fluid?
Are colloid fluids better maintained in theAre colloid fluids better maintained in the intravascular space as compared to crystalloids in
critical illness?
RCT/Yr Population Fluid Comparators
Ratio Colloid/CrystalloidComparators Colloid/Crystalloid
SAFE/04 Critically illN = 6997
4% albumin vs normal saline
1:1.4
VISEP/08 Severe Sepsis/Septic
Shock
10% HES vs ringers lactate
1:1.4
ShockN = 537
McIntyre/08 Septic ShockN = 40
10% HES vs0 9% saline
1:1.1N = 40 0.9% saline
McIntyre/12 Septic ShockN = 50
5% albumin vs0.9% saline
1:1.4
Perner/12 Severe Sepsis and shockN 800
tetraspan vs ringers acetate
1:1.1
N = 800
Finfer et al, NEJM 2004; 350: 2247 - 2256
Finfer et al, NEJM 2004; 350: 2247 - 2256
N = 460
GCS 3 – 12 and an abnormal CTGCS 3 12 and an abnormal CT scan
Myburgh J et al, NEJM 2008; 357: 874 - 884
SAFE TBI: Baseline Characteristics
Albumin (n=231)
Normal Saline (n=229)
Age Median (IQR) 37 (23-55) 35 (23-50)
Male (%) 77.5 73.8
*APACHE II 20.4±6.1 19.7±6.4
*AISS 28.6±9.9 28.2±10.5
*MAP mm Hg 82.5±13.7 84.0±13.7
*CVP H 3 3 3 8*CVP mm Hg 7.3±3.5 7.5±3.8
*GCS 7 (4-9) 7 (5-9)
*ICP 15 0±12 9 12 4±7 2ICP 15.0±12.9 12.4±7.2
Hypotension (%) 30.4 33
* mean±SDMyburgh J et al, NEJM 2008; 357: 874 - 884
Survival in SAFE TBI sub-groupSurvival in SAFE TBI sub group
Survival 28 Days Survival 24 Months
20.4%
Mortality Severe TBI (N = 290)
33.2%RR and 95% CI: 1.88 (1.31 to 1.70)
Predefined sub-group with severe sepsis n = 1218
Finfer et al, Intensive Care Medicine, published on line, October 6, 2010
Baseline Characteristics
CVP missing 707 (58%)n=707 (58%)
Finfer et al, Intensive Care Medicine, published on line, October 6, 2010
Fluids and Co-Interventions
Finfer et al, Intensive Care Medicine, published on line, October 6, 2010
MAP HRMAP HR
CVP ALB
SAFE Severe Sepsis: 28 day mortality
No differences in renal injury
between the fluid groups
Finfer et al, Intensive Care Medicine, published on line, October 6, 2010
What is the evidence for use of albumin for patients who
are hypoalbuminemic?are hypoalbuminemic?
Albumin levels are decreased in the critically ill…..the critically ill…..
• Altered production• Increased degredation• Increased losses• Leak from capillaries
Vincent, JL Best Practise and Research Clinical Anesthesiology 2009; 23: 183 - 191
• Single center, non-blinded RCT pilot study in Brussels, Belgium.
100 patients ith se m alb min < 30 g/L• 100 patients with serum albumin < 30 g/L
• 300 mls of 20% albumin on day 1 followed by 200 mls/day if serum albumin ≤ 30 g/L versus ringers lactate as standard therapy
• Primary Outcome: change SOFA score baseline to day 7
Albumin Control P Value
Delta SOFA 3.1 (1.0) 1.4 (1.1) 0.03
Fluid Gain mls(Mean (SD))
658(1101)
1679(1156)
0.04
Caloric intake Kcal 1122 760 0 05Caloric intake Kcal(Median, IQR)
1122 (935, 1158)
760 (571, 1077)
0.05
Dubois et al. Crit Care Med. 2006; 34: 2536 - 2540
• 6045 patients from SAFE trial
• Baseline serum albumin• Baseline serum albumin levels < 25 versus ≥ 25 g/L
• Resuscitated with normal saline or 4% albumin
Finfer, S et al, BMJ 2006; 333: 1 - 6
What is the evidence for albumin d bili ti f i t titi land mobilization of interstitial
fluid? ARDS Network, NEJM, 2006: 354; 2564 - 2575
Boyd, JH, Critical Care Medicine, 2011: 39; 1 - 7
Hyperoncotic albumin and lasix bi i i icombination: systematic review
• Martin et al: 2 randomized controlled trials• Patient populations: mechanical ventilation with
acute lung injuryacute lung injury• N = 77 patients studied
• Results:• Achievement negative fluid balance
Greater eight loss• Greater weight loss• Improved oxygenation
Thiboutot et al, Am J Respir Crit Care Med 2009: 179, A3089
• 126 patients with cirrhosis and SBP
CefotaximeN = 63
Cefotaxime + albumin
N = 63
P value
• Cefotaxime vs cefotaxime + 20%
lb i
N 63Renalimpairment
21(33) 6(10) 0.002
Death:albumin
P i O t
Death:Hospital3 months
18(29)26(41)
6(10)14(22)
0.010.03
• Primary Outcome:• Renal impairment
Pao, S, NEJM, 1999
5% albumin versus normal saline for resuscitation in early septicfor resuscitation in early septic
shock (PRECISE)
• Design: Multi - center double blind randomized controlled trialSetting 6 Canadian tertiar care centers• Setting: 6 Canadian tertiary care centers
• Population: 50 patients with early suspected septic shock recruited from: emergency department (ED) and g y p ( )intensive care unit (ICU)
• Intervention: Blinded 500 ml boluses of 5% albumin or l li f fl id it ti fi t 7 d i ICUnormal saline for fluid resuscitation first 7 days in ICU
• Primary outcome: Feasibility
McIntyre, L et al, Journal of Critical Care, 2012; 27: 317
Additional albumin in sepsis evidence is l ialso coming…….
ALBIOS Trial EARRS Trial RASP TrialALBIOS Trial EARRS Trial RASP Trial
Population Severe Sepsis/Septic Shock within 24 hours in
ICU
Septic shock within first 6 hours ICU admission
Severe sepsis/septic shock within 6 hours of evolution
Sample Size 1800 800 360
Intervention Open labelUp to 300 mls infused
20% albumin vs crystalloid fluid
according to albumin
Open label100 mls 20% albumin Q8H
versus normal saline for first 3 days in ICU
Blinded 500 ml boluses of 4% albumin versus ringers lactate until CVP is ≥ 8 mm
Hg or recovery from hypotensionaccording to albumin
levels in ICUhypotension
Primary Outcome
28 and 90 Day Mortality
28 Day Mortality 28 Day Mortality
Feast Trial
Maitland et al, NEJM, 2011
Although FEAST was conducted in a pediatric• 3141 African children with febrile illness and impaired perfusion
• Randomized boluses:5% albumin 0 9% saline or no bolus
Although FEAST was conducted in a pediatric patient population, in Africa, with the majority of
children having malaria…..• Randomized boluses:5% albumin, 0.9% saline, or no bolus
Bolus 5% albumin
Bolus normal saline
Control
children having malaria…..
5% albumin normal saline48 hour death 10.6% 10.5% 7.3%
4 week death 12.2% 12.0% 8.7%
Results of FEAST should at least cause us to question some of the very basics of our fluid
it ti tiee deat % 0% 8 %
Neurological sequlae
2.2% 1.9% 2.0%resuscitation practises…….
Increased ICP/ pulmonary edema
2.6% 2.2% 1.7%
A summary of the evidence for lb i i i 2012albumin in sepsis year 2012
• With the present level of evidence 2012:• Consider use for septic shock
A id i t ti b i i j• Avoid use in traumatic brain injury• Mobilization fluid from interstitial space
• Acute lung Injury/Acute respiratory distress syndromeAcute lung Injury/Acute respiratory distress syndrome• Paracentesis for cirrhosis
• More evidence is coming to understand the place of albumin in the critically ill
Thank you for your attention!Thank you for your attention!